-+ 0.00%
-+ 0.00%
-+ 0.00%
Aldeyra Therapeutics Requests FDA Transfer Of ADX-2191 Ind Review For PVRL To Division Of Hematologic Malignancies 2; Withdraws Special Protocol Assessment For ADX-2191 In PVRL; While Jurisdictional Request Is Pending, Does Not Expect To Initiate SPA Clinical Trial For ADX-2191 In PVRL; Regulatory Path For ADX-2191 In PVRL Is Uncertain And May Be Delayed
Share
Listen to the news

https://www.sec.gov/ix?doc=/Archives/edgar/data/1341235/000119312526453537/aldx-20261109.htm

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending